Total Payments
$87,815
2024 Payments
$174.37
Companies
7
Transactions
90
Medicare Patients
982
Medicare Billing
$127,632
Payment Breakdown by Category
Consulting$39,185 (44.6%)
Other$37,461 (42.7%)
Travel$8,245 (9.4%)
Food & Beverage$2,860 (3.3%)
Education$64.19 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $39,185 | 8 | 44.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,461 | 13 | 42.7% |
| Travel and Lodging | $8,245 | 18 | 9.4% |
| Food and Beverage | $2,860 | 49 | 3.3% |
| Education | $64.19 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $83,331 | 76 | $0 (2024) |
| Genentech USA, Inc. | $4,249 | 8 | $0 (2020) |
| United Therapeutics Corporation | $144.87 | 2 | $0 (2024) |
| La Jolla Pharmaceutical Company | $38.07 | 1 | $0 (2023) |
| GlaxoSmithKline, LLC. | $20.43 | 1 | $0 (2020) |
| Insmed, Inc. | $16.24 | 1 | $0 (2020) |
| Mayne Pharma Inc. | $15.86 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $174.37 | 4 | United Therapeutics Corporation ($113.95) |
| 2023 | $13,628 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($13,559) |
| 2022 | $17,975 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($17,975) |
| 2021 | $8,444 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,444) |
| 2020 | $7,615 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,530) |
| 2019 | $22,372 | 22 | Boehringer Ingelheim Pharmaceuticals, Inc. ($22,356) |
| 2018 | $9,633 | 11 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,633) |
| 2017 | $7,974 | 16 | Genentech USA, Inc. ($4,201) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/08/2024 | United Therapeutics Corporation | Steen Solution (Device) | Food and Beverage | Cash or cash equivalent | $113.95 | General |
| Category: Lung Transplant | ||||||
| 07/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: RESPIRATORY | ||||||
| 04/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: RESPIRATORY | ||||||
| 03/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: RESPIRATORY | ||||||
| 12/06/2023 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $38.07 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 11/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| 09/28/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $123.42 | General |
| 05/30/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| 05/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,760.00 | General |
| 05/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $113.72 | General |
| 04/19/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: PAH | ||||||
| 02/26/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $591.33 | General |
| Category: RESPIRATORY | ||||||
| 02/26/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $450.82 | General |
| Category: RESPIRATORY | ||||||
| 02/25/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $39.92 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 09/01/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,815.00 | General |
| Category: RESPIRATORY | ||||||
| 08/31/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $97.85 | General |
| 08/24/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $96.81 | General |
| Category: RESPIRATORY | ||||||
| 06/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,565.00 | General |
| Category: RESPIRATORY | ||||||
| 01/18/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $9,475.00 | General |
| Category: RESPIRATORY | ||||||
| 11/22/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,440.00 | General |
| 11/03/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $119.15 | General |
| 10/29/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $765.96 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 223 | 325 | $82,360 | $26,072 |
| 2022 | 5 | 199 | 274 | $58,696 | $18,379 |
| 2021 | 8 | 276 | 431 | $96,337 | $27,986 |
| 2020 | 9 | 284 | 740 | $200,004 | $55,195 |
Total Patients
982
Total Services
1,770
Medicare Billing
$127,632
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 92 | 135 | $28,029 | $10,514 | 37.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 67 | $20,837 | $6,843 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $11,227 | $3,452 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 30 | $8,787 | $3,081 | 35.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 42 | 57 | $10,659 | $1,302 | 12.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 13 | $2,821 | $879.58 | 31.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 106 | 162 | $34,038 | $12,651 | 37.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $9,324 | $2,977 | 31.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 42 | 61 | $11,407 | $1,393 | 12.2% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 20 | 20 | $3,300 | $1,016 | 30.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 11 | 11 | $627.00 | $341.33 | 54.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 101 | 176 | $38,448 | $13,313 | 34.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 44 | 58 | $9,570 | $2,976 | 31.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 42 | $9,138 | $2,626 | 28.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $8,391 | $2,593 | 30.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 27 | $8,397 | $2,389 | 28.5% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 56 | 87 | $16,269 | $2,128 | 13.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 13 | $4,199 | $1,146 | 27.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 11 | $1,925 | $815.81 | 42.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 286 | $88,946 | $25,898 | 29.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 89 | 154 | $49,742 | $13,488 | 27.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 90 | $19,578 | $5,664 | 28.9% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 55 | 111 | $20,483 | $3,247 | 15.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 39 | $8,541 | $2,429 | 28.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $6,875 | $1,971 | 28.7% |
About Dr. Rade Tomic, MD
Dr. Rade Tomic, MD is a Pulmonary Disease healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548377658.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rade Tomic, MD has received a total of $87,815 in payments from pharmaceutical and medical device companies, with $174.37 received in 2024. These payments were reported across 90 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($39,185).
As a Medicare-enrolled provider, Tomic has provided services to 982 Medicare beneficiaries, totaling 1,770 services with total Medicare billing of $127,632. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Chicago, IL
- Active Since 08/24/2006
- Last Updated 03/19/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1548377658
Products in Payments
- OFEV (Drug) $42,366
- Esbriet (Biological) $4,196
- Steen Solution (Device) $113.95
- Xolair (Biological) $47.95
- GIAPREZA (Drug) $38.07
- TYVASO (Drug) $30.92
- TRELEGY ELLIPTA (Drug) $20.43
- DORYX (Drug) $15.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chicago
Douglas Hogarth
Pulmonary Disease — Payments: $3.0M
Pulmonary Disease $3.0M
Septimiu Murgu
Pulmonary Disease — Payments: $1.0M
Pulmonary Disease $1.0M
Steven White
Pulmonary Disease — Payments: $685,389
Pulmonary Disease $685,389
Ayodeji Adegunsoye
Pulmonary Disease — Payments: $504,729
Pulmonary Disease $504,729
Brian Garibaldi, M.d, M.D
Pulmonary Disease — Payments: $355,981
Pulmonary Disease $355,981
Dr. Ravi Kalhan, M.d, M.D
Pulmonary Disease — Payments: $327,619
Pulmonary Disease $327,619